Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Gout Suppressants"" wg kryterium: Temat


Tytuł :
Fucoidan from Laminaria japonica Inhibits Expression of GLUT9 and URAT1 via PI3K/Akt, JNK and NF-κB Pathways in Uric Acid-Exposed HK-2 Cells.
Autorzy :
Zhang Y; College of Chemistry and Environmental Science, Guangdong Ocean University, Zhanjiang 524088, China.; Guangxi Key Laboratory of Buffalo Genetics, Reproduction and Breeding, Guangxi Buffalo Research Institute, Chinese Academy of Agricultural Sciences, Nanning 530001, China.
Tan X; College of Chemistry and Environmental Science, Guangdong Ocean University, Zhanjiang 524088, China.; Guangxi Key Laboratory of Buffalo Genetics, Reproduction and Breeding, Guangxi Buffalo Research Institute, Chinese Academy of Agricultural Sciences, Nanning 530001, China.
Lin Z; College of Chemistry and Environmental Science, Guangdong Ocean University, Zhanjiang 524088, China.
Li F; College of Chemistry and Environmental Science, Guangdong Ocean University, Zhanjiang 524088, China.
Yang C; Guangxi Key Laboratory of Buffalo Genetics, Reproduction and Breeding, Guangxi Buffalo Research Institute, Chinese Academy of Agricultural Sciences, Nanning 530001, China.
Zheng H; Guangxi Key Laboratory of Buffalo Genetics, Reproduction and Breeding, Guangxi Buffalo Research Institute, Chinese Academy of Agricultural Sciences, Nanning 530001, China.
Li L; Guangxi Key Laboratory of Buffalo Genetics, Reproduction and Breeding, Guangxi Buffalo Research Institute, Chinese Academy of Agricultural Sciences, Nanning 530001, China.
Liu H; College of Chemistry and Environmental Science, Guangdong Ocean University, Zhanjiang 524088, China.
Shang J; Guangxi Key Laboratory of Buffalo Genetics, Reproduction and Breeding, Guangxi Buffalo Research Institute, Chinese Academy of Agricultural Sciences, Nanning 530001, China.
Pokaż więcej
Źródło :
Marine drugs [Mar Drugs] 2021 Apr 23; Vol. 19 (5). Date of Electronic Publication: 2021 Apr 23.
Typ publikacji :
Journal Article
MeSH Terms :
Laminaria*/chemistry
Glucose Transport Proteins, Facilitative/*metabolism
Gout Suppressants/*pharmacology
JNK Mitogen-Activated Protein Kinases/*metabolism
Kidney Tubules, Proximal/*drug effects
NF-kappa B/*metabolism
Organic Anion Transporters/*metabolism
Organic Cation Transport Proteins/*metabolism
Phosphatidylinositol 3-Kinase/*metabolism
Polysaccharides/*pharmacology
Proto-Oncogene Proteins c-akt/*metabolism
Cell Line ; Gout Suppressants/isolation & purification ; Humans ; Kidney Tubules, Proximal/enzymology ; Polysaccharides/isolation & purification ; Signal Transduction ; Uric Acid/toxicity
Czasopismo naukowe
Tytuł :
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Autorzy :
Lazaros G; National and Kapodistrian University of Athens, Athens, Greece .
Tsioufis K; National and Kapodistrian University of Athens, Athens, Greece .
Vassilopoulos D; National and Kapodistrian University of Athens, Athens, Greece .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Apr 15; Vol. 384 (15), pp. 1474-1475.
Typ publikacji :
Letter; Comment
MeSH Terms :
Gout Suppressants*/therapeutic use
Pericarditis*/diagnostic imaging
Pericarditis*/drug therapy
Humans ; Recombinant Fusion Proteins/therapeutic use
Opinia redakcyjna
Tytuł :
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. Reply.
Autorzy :
Klein AL; Cleveland Clinic, Cleveland, OH .
Imazio M; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
Paolini JF; Kiniksa Pharmaceuticals, Lexington, MA.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Apr 15; Vol. 384 (15), pp. 1475-1476.
Typ publikacji :
Letter; Comment
MeSH Terms :
Gout Suppressants*/therapeutic use
Pericarditis*/drug therapy
Humans ; Recombinant Fusion Proteins/therapeutic use
Opinia redakcyjna
Tytuł :
[Colchicine in patients with coronary heart disease : LoDoCo2 trial].
Autorzy :
Koenig W; Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Lazarettstr. 36, 80636, München, Deutschland. .
Nitschmann S; Lippetal, Deutschland.
Pokaż więcej
Transliterated Title :
Colchicin bei Patienten mit koronarer Herzkrankheit : LoDoCo2-Studie.
Źródło :
Der Internist [Internist (Berl)] 2021 Mar; Vol. 62 (3), pp. 333-336. Date of Electronic Publication: 2021 Feb 12.
Typ publikacji :
Journal Article
MeSH Terms :
Colchicine/*administration & dosage
Coronary Artery Disease/*complications
Gout Suppressants/*administration & dosage
Colchicine/adverse effects ; Coronary Artery Disease/drug therapy ; Gout Suppressants/adverse effects ; Humans ; Secondary Prevention/methods ; Tubulin Modulators/administration & dosage ; Tubulin Modulators/adverse effects
Czasopismo naukowe
Tytuł :
The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials.
Autorzy :
Zhang X; Department of endocrinology, China Academy of Chinese Medical Sciences, Beijing, China.
Tang Y; Department of Integrative Chinese and Western Medicine, Central South University, Changsa, Hunan, China.
Wang M; Department of endocrinology, Beijing University of Chinese Medicine, Beijing, China.
Wang D; Institute of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Hunan, China. .
Li Q; Department of general medicine, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. .
Pokaż więcej
Źródło :
Clinical rheumatology [Clin Rheumatol] 2021 Feb; Vol. 40 (2), pp. 701-710. Date of Electronic Publication: 2020 Jun 19.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Gout*/drug therapy
Gout Suppressants*/therapeutic use
Humans ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Uric Acid
Czasopismo naukowe
Tytuł :
Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data.
Autorzy :
Koto R; Medical Science Department, Teijin Pharma Limited, Tokyo, Japan.
Nakajima A; Pharmaceutical Development Administration Department, Teijin Pharma Limited, Tokyo, Japan.
Horiuchi H; Medical Science Department, Teijin Pharma Limited, Tokyo, Japan.
Yamanaka H; Rheumatology Department, Sanno Medical Center, Tokyo, Japan.
Pokaż więcej
Źródło :
Modern rheumatology [Mod Rheumatol] 2021 Jan; Vol. 31 (1), pp. 261-269. Date of Electronic Publication: 2020 Jul 20.
Typ publikacji :
Journal Article
MeSH Terms :
Gout/*drug therapy
Gout Suppressants/*therapeutic use
Hyperuricemia/*drug therapy
Adult ; Female ; Gout Suppressants/administration & dosage ; Humans ; Insurance, Health/statistics & numerical data ; Japan ; Male ; Middle Aged ; Pragmatic Clinical Trials as Topic/statistics & numerical data
Czasopismo naukowe
Tytuł :
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Autorzy :
Mackenzie IS; MEMO Research, Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.
Ford I; The Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Nuki G; Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK.
Hallas J; University of Southern Denmark, Odense, Denmark.
Hawkey CJ; Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, UK.
Webster J; Clinical Pharmacology Unit, University of Aberdeen, Aberdeen, UK.
Ralston SH; Molecular Medicine Centre, University of Edinburgh, Edinburgh, UK.
Walters M; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Robertson M; The Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
De Caterina R; University of Pisa, Pisa University Hospital, and Fondazione VillaSerena per la Ricerca, CittàSant'Angelo, Pescara, Italy.
Findlay E; MEMO Research, Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.
Perez-Ruiz F; Osakidetza, OSI EE-Cruces, Cruces University Hospital-Rheumatology Division, Biskay, Spain.
McMurray JJV; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
MacDonald TM; MEMO Research, Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK. Electronic address: .
Pokaż więcej
Corporate Authors :
FAST Study Group
Źródło :
Lancet (London, England) [Lancet] 2020 Nov 28; Vol. 396 (10264), pp. 1745-1757. Date of Electronic Publication: 2020 Nov 09.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Febuxostat*/administration & dosage
Febuxostat*/adverse effects
Gout Suppressants*/administration & dosage
Gout Suppressants*/adverse effects
Allopurinol/*administration & dosage
Cardiovascular Diseases/*complications
Gout/*drug therapy
Aged ; Denmark ; Female ; Hospitalization ; Humans ; Male ; Prospective Studies ; Sweden ; Treatment Outcome ; United Kingdom ; Uric Acid/blood
Czasopismo naukowe
Tytuł :
Allopurinol and Chronic Kidney Disease.
Autorzy :
Conway R; St. James's Hospital, Dublin, Ireland .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Oct 22; Vol. 383 (17), pp. 1689.
Typ publikacji :
Letter; Comment
MeSH Terms :
Allopurinol*/therapeutic use
Diabetes Mellitus, Type 1*
Gout Suppressants*/adverse effects
Gout Suppressants*/therapeutic use
Renal Insufficiency, Chronic*/drug therapy
Humans ; Uric Acid
Opinia redakcyjna
Tytuł :
Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study.
Autorzy :
Chen SK; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Liu J; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Kim SC; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA .; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, United States.
Pokaż więcej
Źródło :
BMJ open [BMJ Open] 2020 Dec 07; Vol. 10 (12), pp. e041167. Date of Electronic Publication: 2020 Dec 07.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Gout*/drug therapy
Gout*/epidemiology
Gout Suppressants*/adverse effects
Polyethylene Glycols*/adverse effects
Urate Oxidase*/adverse effects
Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Uric Acid
Czasopismo naukowe
Tytuł :
Allopurinol and Chronic Kidney Disease.
Autorzy :
McCormick N; Massachusetts General Hospital, Boston, MA .
Zhang Y; Massachusetts General Hospital, Boston, MA .
Choi HK; Massachusetts General Hospital, Boston, MA .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Oct 22; Vol. 383 (17), pp. 1689-1690.
Typ publikacji :
Letter; Comment
MeSH Terms :
Allopurinol*/therapeutic use
Diabetes Mellitus, Type 1*
Gout Suppressants*/therapeutic use
Renal Insufficiency, Chronic*/drug therapy
Humans ; Uric Acid
Opinia redakcyjna
Tytuł :
Allopurinol and Chronic Kidney Disease.
Autorzy :
Fernandez-Prado R; Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Madrid, Spain .
Ortiz A; Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Madrid, Spain .
Perez-Gomez MV; Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Madrid, Spain .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Oct 22; Vol. 383 (17), pp. 1690.
Typ publikacji :
Letter; Comment
MeSH Terms :
Allopurinol*/therapeutic use
Diabetes Mellitus, Type 1*
Gout Suppressants*/therapeutic use
Renal Insufficiency, Chronic*/drug therapy
Humans ; Uric Acid
Opinia redakcyjna
Tytuł :
Allopurinol and Chronic Kidney Disease. Reply.
Autorzy :
Doria A; Joslin Diabetes Center, Boston, MA .
Galecki AT; University of Michigan, Ann Arbor, MI.
Mauer M; University of Minnesota, Minneapolis, MN.
Pokaż więcej
Corporate Authors :
PERL Study Group
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Oct 22; Vol. 383 (17), pp. 1690-1691.
Typ publikacji :
Letter; Comment
MeSH Terms :
Allopurinol*/therapeutic use
Gout Suppressants*/therapeutic use
Renal Insufficiency, Chronic*/drug therapy
Humans
Opinia redakcyjna
Tytuł :
Allopurinol and Chronic Kidney Disease.
Autorzy :
Kang DH; Ewha University, Seoul, South Korea.
Sanchez-Lozada LG; Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Johnson RJ; University of Colorado Anschutz Medical Center, Aurora, CO .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Oct 22; Vol. 383 (17), pp. 1687-1688.
Typ publikacji :
Letter; Comment
MeSH Terms :
Allopurinol*/therapeutic use
Diabetes Mellitus, Type 1*
Gout Suppressants*/therapeutic use
Renal Insufficiency, Chronic*/drug therapy
Humans ; Uric Acid
Opinia redakcyjna
Tytuł :
Allopurinol and Chronic Kidney Disease.
Autorzy :
Ponticelli C; Via Andrea Maria Ampère 126, Milan, Italy .
Podestà MA; Università degli Studi di Milano, Milan, Italy.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Oct 22; Vol. 383 (17), pp. 1688-1689.
Typ publikacji :
Letter; Comment
MeSH Terms :
Allopurinol*/therapeutic use
Diabetes Mellitus, Type 1*
Gout Suppressants*/therapeutic use
Renal Insufficiency, Chronic*/drug therapy
Humans ; Uric Acid
Opinia redakcyjna
Tytuł :
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Autorzy :
Pan JA; Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, No. 639 Zhizaoju road, Shanghai, 200011, People's Republic of China.
Lin H; Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, No. 639 Zhizaoju road, Shanghai, 200011, People's Republic of China.
Wang CQ; Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, No. 639 Zhizaoju road, Shanghai, 200011, People's Republic of China.
Zhang JF; Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, No. 639 Zhizaoju road, Shanghai, 200011, People's Republic of China. .
Gu J; Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, No. 639 Zhizaoju road, Shanghai, 200011, People's Republic of China. .
Pokaż więcej
Źródło :
Heart and vessels [Heart Vessels] 2020 Oct; Vol. 35 (10), pp. 1446-1453. Date of Electronic Publication: 2020 May 19.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Febuxostat/*administration & dosage
Gout Suppressants/*administration & dosage
Heart Failure/*prevention & control
Hypertension/*complications
Hypertrophy, Left Ventricular/*prevention & control
Hyperuricemia/*drug therapy
Uric Acid/*blood
Ventricular Dysfunction, Left/*prevention & control
Aged ; Asymptomatic Diseases ; Biomarkers/blood ; Blood Pressure ; Databases, Factual ; Diastole ; Disease Progression ; Drug Prescriptions ; Febuxostat/adverse effects ; Female ; Gout Suppressants/adverse effects ; Heart Disease Risk Factors ; Heart Failure/etiology ; Heart Failure/physiopathology ; Humans ; Hypertension/physiopathology ; Hypertrophy, Left Ventricular/etiology ; Hypertrophy, Left Ventricular/physiopathology ; Hyperuricemia/blood ; Hyperuricemia/complications ; Male ; Middle Aged ; Protective Factors ; Retrospective Studies ; Risk Assessment ; Stroke Volume/drug effects ; Time Factors ; Ventricular Dysfunction, Left/etiology ; Ventricular Dysfunction, Left/physiopathology ; Ventricular Function, Left/drug effects ; Ventricular Remodeling/drug effects
Czasopismo naukowe
Tytuł :
Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
Autorzy :
Pruis SL; Agency for Care Effectiveness, Ministry of Health Singapore, Singapore, Singapore.
Jeon YK; Agency for Care Effectiveness, Ministry of Health Singapore, Singapore, Singapore.
Pearce F; Agency for Care Effectiveness, Ministry of Health Singapore, Singapore, Singapore.
Thong BY; Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore.
Aziz MIA; Agency for Care Effectiveness, Ministry of Health Singapore, Singapore, Singapore.
Pokaż więcej
Źródło :
Journal of medical economics [J Med Econ] 2020 Aug; Vol. 23 (8), pp. 838-847. Date of Electronic Publication: 2020 May 13.
Typ publikacji :
Journal Article
MeSH Terms :
Gout/*drug therapy
Gout/*genetics
Gout Suppressants/*economics
Gout Suppressants/*therapeutic use
HLA-B Antigens/*genetics
Allopurinol/economics ; Allopurinol/therapeutic use ; Cost-Benefit Analysis ; Febuxostat/economics ; Febuxostat/therapeutic use ; Genotype ; Gout/ethnology ; Gout Suppressants/administration & dosage ; Gout Suppressants/adverse effects ; Humans ; Kidney Function Tests ; Markov Chains ; Models, Econometric ; Models, Statistical ; Probenecid/economics ; Probenecid/therapeutic use ; Quality-Adjusted Life Years ; Singapore ; Uric Acid/blood
Czasopismo naukowe
Tytuł :
Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine.
Autorzy :
Watanabe H; Nagoya University Graduate School of Medicine, Brain and Mind Research Center, Nagoya.; Fujita Health University School of Medicine, Department of Neurology, Toyoake.
Hattori T; Honmachi Clinic, Naka-ku.
Kume A; KUME Clinic, Mizuho-ku, Nagoya.
Misu K; MISU Clinic, Miyoshi.
Ito T; Saishukan Hospital, Kitanagoya, Aichi.
Koike Y; OASIS Clinic, Ushiku, Ibaraki.
Johnson TA; StaGen Co., Ltd., Taito-ku, Tokyo, Japan.
Kamitsuji S; StaGen Co., Ltd., Taito-ku, Tokyo, Japan.
Kamatani N; StaGen Co., Ltd., Taito-ku, Tokyo, Japan.
Sobue G; Nagoya University Graduate School of Medicine, Brain and Mind Research Center, Nagoya.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Aug 28; Vol. 99 (35), pp. e21576.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms :
Febuxostat/*therapeutic use
Gout Suppressants/*therapeutic use
Inosine/*therapeutic use
Parkinson Disease/*drug therapy
Adenosine Triphosphate/blood ; Administration, Oral ; Aged ; Case-Control Studies ; Drug Therapy, Combination ; Febuxostat/administration & dosage ; Febuxostat/adverse effects ; Female ; Gout Suppressants/administration & dosage ; Gout Suppressants/adverse effects ; Humans ; Hypoxanthine/blood ; Inosine/administration & dosage ; Inosine/adverse effects ; Japan/epidemiology ; Male ; Middle Aged ; Nervous System Diseases/epidemiology ; Parkinson Disease/metabolism ; Parkinson Disease/physiopathology ; Safety ; Treatment Outcome ; Xanthine Dehydrogenase/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
"Kidney Tea" and Its Bioactive Secondary Metabolites for Treatment of Gout.
Autorzy :
Chen WD; State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, People's Republic of China.; University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China.
Zhao YL; State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, People's Republic of China.; Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming, Yunnan 650091, People's Republic of China.
Sun WJ; State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, People's Republic of China.; University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China.
He YJ; Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming, Yunnan 650091, People's Republic of China.
Liu YP; State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, People's Republic of China.
Jin Q; State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, People's Republic of China.; University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China.
Yang XW; State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, People's Republic of China.
Luo XD; State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, People's Republic of China.; Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming, Yunnan 650091, People's Republic of China.
Pokaż więcej
Źródło :
Journal of agricultural and food chemistry [J Agric Food Chem] 2020 Aug 26; Vol. 68 (34), pp. 9131-9138. Date of Electronic Publication: 2020 Aug 14.
Typ publikacji :
Journal Article
MeSH Terms :
Drugs, Chinese Herbal/*administration & dosage
Drugs, Chinese Herbal/*chemistry
Gout/*drug therapy
Gout Suppressants/*administration & dosage
Gout Suppressants/*chemistry
Orthosiphon/*chemistry
Animals ; China ; Drugs, Chinese Herbal/metabolism ; Female ; Gout Suppressants/metabolism ; Humans ; Male ; Mice ; Mice, Inbred ICR ; Molecular Structure ; Orthosiphon/metabolism ; Secondary Metabolism ; Uric Acid/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies